CAS · 89-25-8
Product Overview
Edaravone is a high-purity pharmaceutical-intermediates supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | Light Yellow to Yellow Powder |
|---|---|
| Purity (HPLC) | 99% min |
| Loss on Drying | 1.0% max |
| Ash | 1.0% max |
| Iron (Fe) | 50 ppm max |
Applications
Treatment of Amyotrophic Lateral Sclerosis (ALS)
Edaravone丨89-25-8 is primarily used as a treatment for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that affects motor neurons. It works by reducing oxidative stress, which is thought to contribute to the progression of ALS. Edaravone is approved in several countries as a treatment for ALS, and its use is aimed at slowing the progression of the disease.
Acute Ischemic Stroke
Edaravone is also used in the treatment of acute ischemic stroke. It helps to reduce the damage caused by oxidative stress following the blockage of blood flow to the brain. Edaravone has been shown to provide neuroprotective effects, potentially improving recovery outcomes and reducing long-term disability from ischemic strokes.
Neuroprotective in Other Neurological Conditions
Apart from ALS and stroke, edaravone is being researched for its potential use in other neurological conditions, including Parkinson's disease and Alzheimer's disease. Its antioxidant properties may help protect neurons from oxidative damage in various neurodegenerative diseases.
Oxidative Stress-Related Diseases
Because of its ability to scavenge free radicals and reduce oxidative damage, edaravone is studied for use in other diseases associated with oxidative stress. These conditions include cardiovascular diseases, diabetes, and conditions involving retinal degeneration.
Clinical Research
Edaravone丨89-25-8 is used extensively in clinical research for its potential therapeutic benefits in various diseases related to oxidative stress and neuronal injury. Studies continue to explore its application in areas like brain injury, spinal cord injury, and chronic neurodegenerative diseases.
Benefits
Antioxidant Properties
Edaravone's primary benefit comes from its strong antioxidant properties. It works by scavenging free radicals and reactive oxygen species (ROS), which are damaging to cells, particularly neurons. This antioxidant effect is crucial in treating diseases like ALS and ischemic stroke, where oxidative stress plays a significant role in disease progression.
Slows the Progression of ALS
In ALS, edaravone has been shown to slow the decline in motor function and may extend survival by reducing oxidative stress in the nervous system. This benefit provides hope for ALS patients by potentially improving quality of life and extending functional independence.
Neuroprotective Effects in Stroke
For acute ischemic stroke patients, edaravone offers neuroprotective benefits by limiting brain damage due to oxidative stress following an ischemic event. This can reduce the extent of brain tissue injury, leading to better recovery and reduced long-term disability.
Improves Brain Recovery
In stroke patients, edaravone may improve neurological recovery by protecting brain cells from oxidative damage during the critical period after the stroke. It is particularly beneficial in the early stages following the event, potentially leading to improved outcomes.
Potential Benefits for Other Neurodegenerative Diseases
The neuroprotective properties of edaravone may offer benefits in other neurodegenerative diseases such as Parkinson's and Alzheimer's disease. Its antioxidant activity could slow neuronal damage in these conditions, providing a possible therapeutic avenue for slowing disease progression.
Minimal Side Effects
Compared to other neuroprotective agents, edaravone has a relatively favorable safety profile, with side effects being generally mild and well-tolerated by patients. This makes it an attractive option for long-term use in neurodegenerative diseases like ALS.
Conclusion
Edaravone丨89-25-8 is a potent antioxidant with significant applications in the treatment of neurodegenerative diseases like ALS and ischemic stroke. Its ability to reduce oxidative stress offers benefits in slowing disease progression and improving recovery outcomes in various neurological conditions. As research continues, its potential for treating other oxidative stress-related diseases remains promising. Edaravone's relatively mild side effect profile further enhances its therapeutic appeal for patients with chronic neurological conditions.
Previous
Next